Conference Proceedings

Ibrutinib for the Treatment of Bing-Neel Syndrome

Gilad Itchaki, Jonas Paludo, Maria Lia Palomba, Marzia Varettoni, Dipti Talaulikar, Julio C Chavez, Christian Buske, Alessandra Tedeschi, David Simpson, Constantine S Tam, Samar Issa, Stephen M Ansell, Steven P Treon, Jorge J Castillo

BLOOD | AMER SOC HEMATOLOGY | Published : 2018


Abstract Background: The oral BTK inhibitor ibrutinib is the only approved therapy for patients with symptomatic Waldenström macroglobulinemia (WM). Bing-Neel syndrome (BNS) is a rare complication of WM that results from infiltration of malignant lymphoplasmacytic cells into the central nervous system (CNS) causing neurological deficits. Treatment options in patients with BNS are limited to agents with CNS penetration. Ibrutinib can penetrate into the CNS, but data on its efficacy in BNS is lacking outside case reports. Methods: We performed a multicenter retrospective study evaluating the efficacy of ibrutinib in patients with BNS. The diagnosis of BNS was esta..

View full abstract